01 aoû 2018
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study.
This study aimed to assess the efficacy of DSM265 in patients with P falciparum or Plasmodium vivax malaria infection.